Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$14.09 USD
+0.62 (4.60%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $14.10 +0.01 (0.07%) 6:10 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Viridian Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -237.73 | -129.87 | -79.41 | -110.72 | -41.87 |
Depreciation/Amortization & Depletion | -10.97 | 0.05 | 1.17 | 0.58 | -0.14 |
Net Change from Assets/Liabilities | -9.43 | 15.96 | 1.72 | 4.43 | 1.65 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 73.96 | 20.03 | 21.94 | 75.93 | 4.31 |
Net Cash From Operating Activities | -184.17 | -93.84 | -54.58 | -29.78 | -36.06 |
Property & Equipment | -0.90 | -0.80 | -0.26 | -0.04 | -0.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 29.37 | 0.00 |
Investments | -93.35 | -114.33 | -74.03 | -79.81 | 28.31 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -94.25 | -115.13 | -74.29 | -50.48 | 28.23 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 222.99 | 339.75 | 133.55 | 111.23 | 2.48 |
Issuance (Repayment) of Debt | 15.00 | 5.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -8.57 | -2.33 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -12.32 | -22.51 | -8.28 | -1.35 | -0.08 |
Net Cash from Financing Activities | 225.67 | 322.24 | 125.28 | 101.31 | 0.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -52.75 | 113.28 | -3.60 | 21.05 | -7.76 |
Cash at Beginning of Period | 155.58 | 42.30 | 45.90 | 24.85 | 32.61 |
Cash at End of Period | 102.83 | 155.58 | 42.30 | 45.90 | 24.85 |
Diluted Net EPS | -5.31 | -4.05 | -6.66 | -31.13 | -20.09 |
Fiscal Year End for Viridian Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -113.54 | -48.54 | -237.73 | -170.87 | -123.21 |
Depreciation/Amortization & Depletion | -8.78 | -4.52 | -10.97 | -8.05 | -5.65 |
Net Change from Assets/Liabilities | 6.17 | -4.96 | -9.43 | -15.04 | -10.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 24.87 | 12.80 | 73.96 | 47.80 | 32.63 |
Net Cash From Operating Activities | -91.28 | -45.22 | -184.17 | -146.17 | -107.19 |
Property & Equipment | -0.10 | 0.00 | -0.90 | -0.85 | -0.45 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -80.97 | -143.05 | -93.35 | 76.31 | 27.86 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -81.07 | -143.05 | -94.25 | 75.46 | 27.42 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 177.19 | 187.46 | 222.99 | 12.24 | 11.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 15.00 | 15.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -10.38 | -12.32 | -0.51 | 0.00 |
Net Cash from Financing Activities | 177.19 | 177.08 | 225.67 | 26.73 | 11.27 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 4.84 | -11.19 | -52.75 | -43.98 | -68.50 |
Cash at Beginning of Period | 102.83 | 102.83 | 155.58 | 155.58 | 155.58 |
Cash at End of Period | 107.67 | 91.64 | 102.83 | 111.60 | 87.08 |
Diluted Net EPS | -1.02 | -0.79 | -1.34 | -1.09 | -1.27 |